Interest in cancer vaccines is being reignited by a greater understanding of tumor immunology and the potential of combining immunogens with new breakthrough immunotherapies.
Subscribe to Journal
Get full journal access for 1 year
only $20.83 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Schumacher, T.N. & Schreiber, R.D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).
Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641–645 (2014).
Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350, 1387–1390 (2015).
Bouchie, A. & DeFrancesco, L. Nature Biotechnology's academic spinouts of 2015. Nat. Biotechnol. 34, 484–492 (2016).
Le, D.T. et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 36, 382–389 (2013).
Lutz, E.R., Kinkead, H., Jaffee, E.M. & Zheng, L. Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. OncoImmunology 3, e962401 (2014).
Garde, D. Aduro slips after trial patient comes down with a dangerous infection. Fierce Biotech, 24 November http://www.fiercebiotech.com/r-d/aduro-slips-after-trial-patient-comes-down-a-dangerous-infection (2015).
Feuerstein, A. Advaxis cancer immunotherapy on hold due to patient death. The Street, 6 October https://www.thestreet.com/story/13314660/1/advaxis-cancer-immunotherapy-on-hold-due-to-patient-death.html (2015).
Jochems, C. et al. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol. Immunother. 63, 407–418 (2014).
Chen, D.S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).
Alexandrov, L.B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
Gulley, J.L. et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin. Cancer Res. 11, 3353–3362 (2005).
Fong, L. et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J. Natl. Cancer Inst. 106, dju268 (2014).
Sheikh, N. et al. Clonotypic diversification of intratumoral T cells following Sipuleucel-T treatment in prostate cancer subjects. Cancer Res. 76, 3711–3718 (2016).
Cha, E. et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci. Transl. Med. 6, 238ra70 (2014).
About this article
Possible Abscopal Effect Observed in Frontal Meningioma After Localized IMRT on Posterior Meningioma Resection Cavity Without Adjuvant Immunotherapy
Frontiers in Oncology (2019)
Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors
Pathology - Research and Practice (2019)
ACS Nano (2019)
The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018
Acta Oncologica (2019)
Genome Medicine (2019)